首页> 外文期刊>Journal of clinical laboratory analysis. >Comparative Study of Immunofluorescent Antinuclear Antibody Test and Line Immunoassay Detecting 15 Specific Autoantibodies in Patients With Systemic Rheumatic Disease
【24h】

Comparative Study of Immunofluorescent Antinuclear Antibody Test and Line Immunoassay Detecting 15 Specific Autoantibodies in Patients With Systemic Rheumatic Disease

机译:系统性风湿病患者免疫荧光抗核抗体测试与线免疫分析检测15种特异性自身抗体的比较研究

获取原文
           

摘要

Based on the currently proposed algorithms, antibodies specificities (sp-ANAs) are identified mainly in samples positive for fluorescent antinuclear antibodies (FANA) screening tests. The purpose of the present study was to compare diagnostic performances of FANA and line immune assay (LIA) detecting 15 sp-ANAs in patients with systemic rheumatic diseases (SRD). In 948 sera from the patients with SRD (n = 590) and non-SRD (n = 358), we evaluated the fluorescent patterns and intensities in the FANA test, and compared the FANA results with sp-ANAs against nRNP, Sm, SS-A, Ro52, SS-B, Scl-70, PM/Scl, Jo-1, CENP B, PCNA, dsDNA, nucleosome, histone, ribosomal-P, and M2. The sensitivity and specificity was 75.9% and 52.5% of FANA test and 62.0% and 84.4% of sp-ANAs test for SRD detection. The overall agreement between FANA and sp-ANAs results was 69.2% (Kappa coefficient; 0.404). According to the clinical diagnosis, the levels of agreement varied from 33.3% to 83.1%. The positive predictive values of each FANA pattern for the detection of sp-ANAs were less than 50% except for the discrete speckled pattern (91.7%). The 1:100 intensity of FANA as well as the monoreactivity of LIA, anti-SSA(?)/anti-Ro52(+), or FANA(?)/sp-ANAs(+) was associated with non-SRD. Antibodies against ribosomal-P or PCNA were specific for systemic lupus eryhthematosus. This study highlights the need for careful interpretation of FANA test results to assess sp-ANAs and the application of sp-ANAs tests including less-common autoantibodies. In patients with clinical suspicion of SRD, screening with both FANA and sp-ANAs tests could improve diagnostic efficiency. J. Clin. Lab. Anal. 26:307-314, 2012. ? 2012 Wiley Periodicals, Inc.
机译:基于当前提出的算法,主要在荧光抗核抗体(FANA)筛选试验呈阳性的样品中鉴定抗体特异性(sp-ANA)。本研究的目的是比较FANA和线免疫测定(LIA)在系统性风湿病(SRD)患者中检测15种sp-ANA的诊断性能。在SRD(n = 590)和非SRD(n = 358)患者的948份血清中,我们在FANA测试中评估了荧光模式和强度,并将spANAS对nRNP,Sm,SS的FANA结果进行了比较。 -A,Ro52,SS-B,Scl-70,PM / Scl,Jo-1,CENP B,PCNA,dsDNA,核小体,组蛋白,核糖体P和M2。 SRD检测的敏感性和特异性分别为FANA测试的75.9%和52.5%,以及sp-ANAs测试的62.0%和84.4%。 FANA与sp-ANAs结果之间的总体一致性为69.2%(Kappa系数; 0.404)。根据临床诊断,一致性水平从33.3%到83.1%不等。除散斑图样(91.7%)外,每个FANA图样对sp-ANAs的阳性预测值均小于50%。 FANA的1:100强度以及LIA,抗SSA(α)/抗Ro52(+)或FANA(α)/ sp-ANAs(+)的单反应性与非SRD相关。针对核糖体P或PCNA的抗体对系统性红斑狼疮具有特异性。这项研究强调需要仔细解释FANA测试结果以评估sp-ANA,以及sp-ANAs测试的应用,包括较少见的自身抗体。在临床上怀疑有SRD的患者中,同时进行FANA和sp-ANAs检测可以提高诊断效率。 J.临床。实验室肛门26:307-314,2012。 2012 Wiley期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号